Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide

Clinical Pharmacokinetics

Volumn 56, Issue 7, 2017, Pages 719-731

  Brønden, Andreas ^a   Knop, Filip K ^a,b   Christensen, Mikkel B ^a,b,c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c BISPEBJERG HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALBIGLUTIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; LIRAGLUTIDE; PLACEBO; SIMVASTATIN; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; RECOMBINANT PROTEIN; RGLP-1 PROTEIN;

BODY WEIGHT; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; DIARRHEA; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; IMMUNOGENICITY; INJECTION SITE REACTION; KIDNEY FUNCTION; META ANALYSIS (TOPIC); NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREATITIS; PHARMACODYNAMICS; PHARMACOKINETIC PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; VOMITING; WEIGHT REDUCTION; ANALOGS AND DERIVATIVES; ANIMAL; TREATMENT OUTCOME;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 85008147840     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-016-0499-8     Document Type: Review

References (44)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38:140–9.
2. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ. 2011;343:d4169.
3. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014;383:1068–83.
4. Göke B. Islet cell function: alpha and beta cells: partners towards normoglycaemia. Int J Clin Pract Suppl. 2008;159:2–7.
5. Meier JJ, Nauck MA. Is the diminished incretin effect in type 2 diabetes just an epi-phenomenon of impaired beta-cell function? Diabetes. 2010;59:1117–25.
6. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004;287:E199–206.
7. Nauck MA, Homberger E, Siegel EG, et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. J Clin Endocrinol Metab. 1986;63:492–8.
8. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87:1409–39.
9. Hare KJ, Knop FK. Incretin-based therapy and type 2 diabetes. Vitam Horm. 2010;84:389–413.
10. Thazhath SS, Marathe CS, Wu T, et al. The glucagon-like peptide-1 receptor agonist exenatide inhibits small intestinal motility, flow, transit, and absorption of glucose in healthy subjects and patients with type 2 diabetes: a randomised controlled trial. Diabetes. 2016;65:269–75.
11. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998;101:515–20.
12. European Medicines Agency. Eperzan (European Public Assessment Report). Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPARPublic_assessment_report/human/002735/WC500165119.pdf. Accessed 2 Aug 2016.
13. Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44:1126–31.
14. Trujillo JM, Nuffer W. Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Ann Pharmacother. 2014;48:1494–501.
15. Blair HA, Keating GM. Albiglutide: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2015;75:651–63.
16. Hottenstein CS, Szapacs ME, Maier CC. Investigation of blood-brain barrier penetration of albiglutide in mice. 76th Scientific Sessions of the American Diabetes Association. New Orleans, 10-14 June 2016;1044-P.
17. Leiter LA, Jones-Leone A, Acusta A, et al. Effects of mild to moderate renal impairment on albiglutide in type 2 diabetes. 76th Scientific Sessions of the American Diabetes Association. New Orleans, 10-14 June 2016;1020-P.
18. US Food and Drug Administration. Tanzeum (albiglutide): prescribing information. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125431s009lbl.pdf. Accessed 25 Jul 2016.
19. European Medicines Agency. Eperzan: product information. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Product_Information/human/002735/WC500165117.pdf. Accessed 25 Jul 2016.
20. Young MA, Wald JA, Matthews JE, et al. Effect of renal impairment on the pharmacokinetics, efficacy, and safety of albiglutide. Postgrad Med. 2014;126:35–46.
21. Bush M, Scott R, Watanalumlerd P, et al. Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive. Postgrad Med. 2012;124:55–72.
22. Hompesch M, Jones-Leone A, Carr MC, et al. Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2015;17:82–90.
23. Nauck MA, Kemmeries G, Holst JJ, Meier JJ. Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans. Diabetes. 2011;60:1561–5.
24. Umapathysivam MM, Lee MY, Jones KL, et al. Comparative effects of prolonged and intermittent stimulation of the glucagon-like peptide 1 receptor on gastric emptying and glycemia. Diabetes. 2014;63:785–90.
25. US Food Drug Administration, Center for Drug Evaluation and Research. Clinical pharmacology review, albiglutide (GSK716155). Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125431Orig1s000ClinPharmR.pdf. Accessed 5 Aug 2016.
26. Darpo B, Zhou M, Matthews J, et al. Albiglutide does not prolong QTc interval in healthy subjects: a thorough ECG study. Diabetes Ther Res Treat Educ Diabetes Relat Disord. 2014;5:141–53.
27. Fisher M, Petrie MC, Ambery PD, et al. Cardiovascular safety of albiglutide in the HARMONY programme: a meta-analysis. Lancet Diabetes Endocrinol. 2015;3:697–703.
28. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22.
29. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44.
30. Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247–57.
31. Rosenstock J, Reusch J, Bush M, et al. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care. 2009;32:1880–6.
32. Seino Y, Nakajima H, Miyahara H, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus. Curr Med Res Opin. 2009;25:3049–57.
33. Seino Y, Inagaki N, Miyahara H, et al. A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus. Curr Med Res Opin. 2014;30:1095–106.
34. Reusch J, Stewart MW, Perkins CM, et al. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin. Diabetes Obes Metab. 2014;16:1257–64.
35. Nauck MA, Stewart MW, Perkins C, et al. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia. 2016;59:266–74.
36. Ahrén B, Johnson SL, Stewart M, et al. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37:2141–8.
37. Home PD, Shamanna P, Stewart M, et al. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5. Diabetes Obes Metab. 2015;17:179–87.
38. Weissman PN, Carr MC, Ye J, et al. HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea. Diabetologia. 2014;57:2475–84.
39. Rosenstock J, Fonseca VA, Gross JL, et al. Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro. Diabetes Care. 2014;37:2317–25.
40. Leiter LA, Carr MC, Stewart M, et al. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study. Diabetes Care. 2014;37:2723–30.
41. Pratley RE, Nauck MA, Barnett AH, et al. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014;2:289–97.
42. Phillips LK, Rayner CK, Jones KL, et al. Measurement of gastric emptying in diabetes. J Diabetes Complications. 2014;28:894–903.
43. Petersen AB, Christensen M. Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2013;6:217–31.
44. Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf. 2007;30:1127–42.